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Editorial on the Research Topic
Resistance to Endocrine Therapies in Cancer
Therapeutic resistance in cancer is one of the major and persistent problems in disease
management. It is a major challenge for radiotherapy as well as both targeted and non-targeted
chemotherapies. Understanding of the underlying genetic, epigenetic and signaling mechanisms,
both within the tumor (intrinsic) as well as in the tumor microenvironment (extrinsic) would
facilitate development of better disease management strategies.
Endocrine therapy refers to a group of chemotherapies which are targeted to disrupt hormonal
signaling pathways. The most commonly targeted pathways are the estrogen and androgen
signaling pathways, which have major roles to play in the cancers of breast and prostate,
respectively. Breast cancer is the second most common cancer among women and prostate
the second among men1. Both these organs and also the cancers originating in these organs
are heavily dependent on the steroid hormones for their growth, survival and proliferation.
Hence, the obvious choice of first line of therapy for these cancers is to disrupt the steroid
hormone synthesis and action, i.e., endocrine therapy. Although initially very effective, a majority
of the hormone-dependent cancers develop resistance to hormonal ablation and evolve into
a hormone-independent phenotype, rendering the endocrine therapies ineffective. Once this
refractoriness sets in, the cancers become very aggressive and difficult to treat.Whether it is primary
or adaptive/acquired resistance to endocrine therapy, it remains a yet unsolved clinical challenge.
For the last several years, attempts have been made to understand the mechanisms responsible
for resistance to endocrine therapies with the aim of developing more effective and less toxic
treatment strategies. Among the relatively well-understood mechanisms of endocrine therapy
resistance are de novomutations in the hormone receptor genes such as ESR 1 and ESR 2, although
seen in a small percentage of cases. Differential activation of signaling pathways such as PI3K/Akt
and Ras-MAPK is seen more often in tumors with acquired resistance. Aberrations in cell cycle
regulators such as Cyclin D1, RB, or MYC and activation of receptor tyrosine kinases (examples
ErbB2, FGFR, IR, IGF1R) have also been implicated in development of endocrine therapy resistance
[reviewed in (1)]. More recently, alterations in autophagy (2), metabolism (3), etc. have been
associated with acquisition of endocrine-therapy resistance.
1Available online at: www.cancer.org.
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This collection of articles attempts to provide a comprehensive
picture of the challenges faced due to emergence of resistance
to endocrine therapies in breast cancer and an insight into
the current understanding of the mechanisms underlying the
same. The article collection includes comprehensive reviews on
the role of mutations in estrogen receptors and the role of
alternative signaling pathways such as PI3K/Akt, mTOR etc. in
the development of endocrine resistance in breast cancer (Rani
et al.; Haque and Desai). Over the last decade, the role of the
tumor niche in metastasis, relapse, and therapeutic resistance
has been gaining a lot of importance. An article by Dr. Simian’s
group gives an overview of the various microenvironment
components and their influence on endocrine therapy in breast
cancer (Diaz Bessone et al.). Another article by Dr. Ranganathan’s
group gives an insight into the role of non-canonical estrogen
Abbreviations: PI3K, Phosphatidylinositol 3-kinase; Akt, Alias Protein Kinase
B, a serine/threonine kinase; MAPK, Mitogen Activated Protein Kinase; RB,
Retinoblastoma; ErbB2, A receptor tyrosine kinase, also known as HER2 (from
human epidermal growth factor receptor 2); FGFR, Fibroblast Growth Factor
Receptor; IR, Insulin Receptor; IGF1R, Insulin Like Growth Factor 1 Receptor;
mTOR, Mammalian Target of Rapamycin; 3D genome, Three Dimensional
Genome; ESR, Gene coding for estrogen receptor.
receptors in conferring endocrine resistance (Ranganathan et al.).
Despite comprehensive coverage of current status of research
in these areas, some aspects such as the role of autophagy, the
effect of changes in the organization of the 3D genome, etc.
on endocrine resistance would be important to gain a better
understanding of the phenomenon and in developing better
strategies for treatment. This endeavor has brought together
different research groups and we hope that this can lead to
improved collaborative research.
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